Table 3.
Comparison of pre and post-RTX CT scan score, PFT measurements, and prednisone dose for all subjects with follow-up at 1–3 years (n=25). Mean ± SD presented.
| Baseline | 1 Year Follow-up | 2 Year Follow-up | 3 Year Follow-up | |
|---|---|---|---|---|
| CT Scan | ||||
| Average score | 194 ± 58 n=15 |
195 ± 55 n=8 |
187 ± 52 n=5 |
161 ± 55 n=4 |
|
Paired average Δ (p-value)* |
N/A | −2.0 (0.84) |
−0.9 (0.88) |
−38.9 (0.63) |
| Improved/Stable** | N/A | 2/5 (88%) | 0/4 (80%) | 1/2 (75%) |
| PFTs | ||||
| FVC% | 57 ± 17 n=22 |
60 ± 20 n=19 |
65 ± 22 n=12 |
82 ± 20 n=7 |
|
Paired average Δ (p-value) |
N/A | +3.7 (0.18) |
+7.7 (0.15) |
+21.1 (0.016) |
| Improved/Stable | N/A | 8/7 (79%) | 6/4 (83%) | 7/0 (100%) |
| TLC% | 56 ± 13 n=7 |
64 ± 13 n=7 |
67 ± 24 n=5 |
75 ± 19 n=2 |
|
Paired average Δ (p-value) |
N/A | +8.3 (0.016) |
+8.6 (0.44) |
+23.5 (0.50) |
| DLCO% | 42 ± 17 n=19 |
36 ± 16 n=17 |
53 ± 26 n=9 |
70 ± 20 n=4 |
|
Paired average Δ(p-value) |
N/A | −3.34 (0.46) |
+9.6 (0.074) |
+14.8 (0.25) |
| Prednisone | ||||
| Average Dose | 18 ± 9 n=20 |
12 ± 12 n=17 |
10 ± 8 n=6 |
6 ± 6 n=4 |
|
Paired average Δ (p-value) |
N/A | −6.2 (0.041) |
−3.3 (0.63) |
−15.1 (0.13) |
| Improved/Stable | N/A | 11/4 (88%) | 2/2 (67%) | 4/0 (100%) |
Paired average Δ represents difference in the mean of paired observations with the p-value as calculated using the Wilcoxon signed rank test. A p-value of <0.05 was considered significant.
Improved is defined by >10% decrease in CT score or >10 improvement in FVC%. Stable is defined by <10% increase in CT score or <10 decline in FVC% (Pioped criteria). Values are compared to baseline time point.
Abbreviations: RTX – Rituximab, CT – Computed tomography, PFTs - Pulmonary function tests, SD – Standard deviation, FVC% - Forced vital capacity (% predicted), TLC% - Total lung capacity (% predicted), DLCO% - Diffusion capacity of carbon monoxide (% predicted)